Zota Health Care Peer Comparison

NSE: ZOTA

₹1,132.40

₹31.20 (2.83%)

As on 04-Sep-2026 15:56IST

Market cap

₹3,922 Cr

Revenue (TTM)

₹609 Cr

P/E Ratio

P/B Ratio

6.2

Div. Yield

0.1 %

Edit

	Zota Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	3,922	33,908	29,353	28,517	25,923
Revenue (₹ Cr)	609	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-104.24	414.00	288.22	-371.81	387.35
Net Margin (%)	-16.89	11.23	14.79	-3.93	26.01
RoE (%)	-19.81	8.38	29.77	-3.85	25.18
Price to Earnings	--	82.90	101.84	--	67.12
Price-To-Book	6.17	6.74	21.87	3.56	15.02

Income Statement (₹ Cr)

	Zota Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	608.68	3,564.00	1,935.80	9,205.28	1,461.80
Total Income	617.28	3,686.00	1,948.58	9,449.59	1,489.25
Total Expenditure	605.69	2,792.00	1,485.56	8,195.15	919.25
EBITDA	2.99	772.00	450.24	1,010.13	542.56
Depreciation	95.52	226.00	50.83	857.51	37.68
EBIT	-92.54	546.00	399.41	152.62	504.88
Interest	20.47	217.00	40.84	342.73	3.77
Other Income	8.61	122.00	12.78	244.31	27.45
Exceptional Items	-6.00	12.00	0.00	-216.88	0.00
Profit before Tax	-110.41	463.00	371.35	-162.68	528.56
Provision for Tax	-6.16	49.00	83.14	209.13	141.21
Profit after Tax	-104.24	414.00	288.22	-371.81	387.35

	Zota Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	693.49	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	1.07	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	197.61	1,712.00	202.03	5,044.14	42.40
Current Liabilities	237.27	1,622.00	835.87	4,758.28	230.82
Total Liabilities	439.14	8,100.00	1,451.43	15,513.53	1,549.26

	Zota Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	449.53	5,343.00	519.60	10,211.52	1,026.85
Current Assets	457.17	2,606.00	1,681.81	7,191.66	881.27
Total Assets	439.14	8,100.00	1,451.43	15,513.53	1,549.26
Total Debt*	5.60	1,859.00	393.17	4,720.27	8.18
Net Current Assets	219.89	984.00	845.94	2,433.38	650.46
Contingent Liabilities	--	770.26	12.25	99.76	15.38

	Zota Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-49.96	-22.00	159.18	892.30	118.34
Cash Flow from Investing Activities	-92.19	-783.00	-64.81	-477.46	-223.94
Cash from Financing Activities	144.76	409.00	-39.81	-440.83	261.12
Net Cash Inflow / Outflow	2.61	-396.00	54.56	-25.99	155.52

	Zota Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-28.07	4.07	26.97	6.61	20.14
ROE (%)	-19.81	8.38	29.77	-3.85	25.18
ROA (%)	-13.28	4.94	24.77	-2.21	21.93
EBIT Margin (%)	-15.20	15.32	20.63	1.66	34.54
Net Margin (%)	-16.89	11.23	14.79	-3.93	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Zota Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	78.89	18.37	46.65	0.78	40.90
EBIT Growth (%)	-83.73	252.26	62.13	-70.53	124.50
Net Profit Growth (%)	-80.38	377.85	89.49	-1,383.43	104.15
EPS Growth (%)	-44.76	1,001.33	78.60	-484.84	42.32
Book Value Growth (%)	148.60	29.77	42.49	2.28	94.96

	Zota Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	-38.16	85.09	100.28	-91.14	67.12
Price / Book Value	6.17	6.74	21.87	3.56	15.02
Dividend Yield (%)	0.09	0.00	0.08	0.00	0.08
EV/EBITDA	1,314.50	45.82	65.00	32.33	47.41
Market Cap (₹ Cr)	2,306.11	23,064.69	0.00	29,731.27	19,988.69

	Zota Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.01	0.31	0.11	0.53	0.01
Short term debt to equity ratio	0.00	0.11	0.54	0.12	0.02
Current Ratio	1.93	1.61	2.01	1.51	3.82
Quick Ratio	1.11	1.06	1.14	0.87	2.82
Interest Coverage	-4.39	3.13	10.09	0.53	141.16

	Zota Health Care	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	12.08	16.50	26.28	23.44	24.80
Asset Turnover	0.78	0.43	1.66	0.55	0.83
Receivable days	42.20	60.36	47.59	77.05	90.06
Inventory Days	99.32	64.42	62.58	77.13	61.02
Payable days	101.03	218.94	228.78	173.49	96.06
Cash Conversion Cycle	40.50	-94.15	-118.62	-19.30	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.